HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Investor Deadline Established
News provided by
Share this article
Class Period: Nov. 8, 2019 – Apr. 6, 2021
Lead Plaintiff Deadline: June 11, 2021
Securities Fraud Action:
The complaint centers on FibroGen s presentation of false data of roxadustat to make the anemia drug look safer than it is.
Throughout the Class Period, FibroGen touted the prospects of roxadustat. A key selling point for the drug was its purported heart safety as compared to standard of care erythropoietin (EPO) injectable therapies, which cannot be proscribed to a variety of patients at risk of major cardiac events. To support this marketing edge, FibroGen presented data from phase 3 trials purportedly showing roxadustat was safer than EPO, among other a
844-916-0895
Ubiquiti Inc. (NYSE: UI) Investigation:
The investigation focuses on whether Ubiquiti accurately reported the nature and scope of a recent security breach incident.
On Jan. 11, 2021, Ubiquiti urged customers to change their passwords and enable multi-factor authentication after it became aware of unauthorized access to certain of its information technology systems hosted by a third-party cloud provider. The company, however, downplayed the seriousness of the incident, advising its customers that it was not currently aware of evidence of access to databases that host user data.
But on March 30, 2021,
KrebsonSecurity published an article entitled, Whistleblower: Ubiquiti Breach Catastrophic, reporting that a Ubiquiti security professional who helped the company respond to the two-month breach beginning in December 2020 informed
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Amdocs Limited (DOX) Investors with Losses to Contact Its Attorneys Now, Analyst Calls Shares Uninvestable
News provided by
Share this article
SAN FRANCISCO, April 1, 2021 /PRNewswire/ Hagens Berman urges Amdocs Limited (NASDAQ: DOX)
investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims.
844-916-0895
The investigation focuses on the accuracy of Amdocs reported financial results.
In past quarters, Amdocs repeatedly touted its strong sequential revenue growth, margins, and strong balance sheet.
But on March 31, 2021, these and other company representations were brought into question when
/PRNewswire/ Hagens Berman urges SOS Limited (NYSE: SOS) investors to submit their losses now. Class Period: July 22, 2020 – Feb. 25, 2021 Lead Plaintiff.